Weber Richard W
National Jewish Medical and Research Center, University of Colorado Health Sciences Center, Denver, Colorado, USA.
Curr Opin Allergy Clin Immunol. 2005 Dec;5(6):563-9. doi: 10.1097/01.all.0000191240.28255.ab.
This review will summarize recent research on pollen allergen and epitope cross-reactivity. Knowledge of these relationships aids in the rational formulation of allergen immunotherapy vaccines.
There has been further clarification of panallergens and their roles as both major and minor allergens. Recent studies have targeted non-specific lipid transfer proteins and calcium-binding proteins (polcalcins), as well as pathogenesis-related protein families and profilins. Polcalcins and non-specific lipid transfer proteins are responsible for pollen-fruit interactions as well as pollen cross-reactivity, in some cases, but not all, accounting for major allergenicity. Delineation of the enzymatic activity of certain allergens explains the ubiquitous nature of these pollen proteins.
Characterization of specific pollen allergens and their protein families has provided insight into the grounds for cross-reactivity. Continuing clarification of these relationships will allow the substitution and consolidation of inhalant extracts as described in the conclusion.
本综述将总结近期关于花粉过敏原和表位交叉反应性的研究。了解这些关系有助于合理制定过敏原免疫治疗疫苗。
对泛过敏原及其作为主要和次要过敏原的作用有了进一步的阐明。近期研究聚焦于非特异性脂质转移蛋白和钙结合蛋白（多聚钙蛋白），以及病程相关蛋白家族和肌动蛋白结合蛋白。在某些情况下，但并非所有情况，多聚钙蛋白和非特异性脂质转移蛋白导致花粉与果实的相互作用以及花粉交叉反应性，并构成主要变应原性。对某些过敏原酶活性的描述解释了这些花粉蛋白的普遍存在特性。
特定花粉过敏原及其蛋白家族的特征已为交叉反应性的依据提供了见解。如结论所述，持续阐明这些关系将有助于吸入性提取物的替代和整合。
